Last reviewed · How we verify
pregabalin 450 mg
At a glance
| Generic name | pregabalin 450 mg |
|---|---|
| Sponsor | Viatris Specialty LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia (NA)
- The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia (NA)
- Efficacy and Safety of Pregabalin/Tizanidine vs. Pregabalin in Patients With Fibromyalgia (NA)
- The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia (NA)
- The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia (NA)
- Crisugabalin for Radiotherapy-Related Neuropathic Pain (PHASE2)
- Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)
- Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pregabalin 450 mg CI brief — competitive landscape report
- pregabalin 450 mg updates RSS · CI watch RSS
- Viatris Specialty LLC portfolio CI